NCT03039790 - Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults | Biotech Hunter

Enrollment

528

Participants

Timeline

Start Date

February 21, 2017

Primary Completion Date

July 22, 2021

Study Completion Date

July 22, 2021

Conditions

Healthy VolunteersNorovirus

Interventions

BIOLOGICAL

NoV Vaccine

NoV vaccine injection administered.

Trial Locations (11)

Universiteit Antwerpen, Antwerp

Universitair Ziekenhuis Gent, Ghent

Regional Clinical Research Inc., Endwell

University of Rochester, Rochester

Miami Research Associates, Miami

Simon-Williamson Clinic/Synexus Clinical Research US, Inc, Birmingham

St. Louis University, School of Medicine, St Louis

Johnson County Clin-Trials, Lenexa

Benchmark Research Austin, Austin

Synexus Clinical Research US, Inc/Southwest Family Medicine, Littleton

Synexus Clinical Research US, Inc./Fountain Hills Family Practice, P.C., Fountain Hills